The State of Pharmaceutical Cold Chain in India: Challenges, Regulations, and the Path to Global Excellence
KELZIX Research · · 12 min read
Cold Chain · Regulations · India · GDP Compliance
Key Highlights
- India supplies approximately 50% of global vaccine demand and 20% of the world’s generic medicines (WHO, Pharmexcil).
- The WHO estimates that up to 50% of vaccines may be wasted globally, partly due to cold chain failures.
- CDSCO GDP guidelines require continuous temperature monitoring with electronic records and audit trails.
- Compliance with WHO, US FDA, and EU GDP standards is essential for export market access.
1. The Current State of Cold Chain Infrastructure in India
India, often referred to as the “pharmacy of the world,” supplies nearly half of global vaccine demand and a fifth of the world’s generic medicines. Despite this strength, a major challenge threatens both domestic healthcare delivery and export potential: inadequate pharmaceutical cold chain infrastructure.
The pharmaceutical cold chain ensures medicines remain effective from manufacturing to patient delivery. However, it remains one of the most underdeveloped aspects of India's pharmaceutical ecosystem.
Many existing cold storage facilities were originally designed for agricultural products and lack advanced monitoring capabilities required for pharmaceutical storage.
Pharmaceutical cold chains require:
- Continuous temperature monitoring
- Deviation management protocols
- Regulatory documentation and audit trails
- Calibrated equipment with traceable standards
Temperature excursions can significantly reduce drug efficacy. For biologics, vaccines, and insulin products, even brief exposure outside the 2–8°C range can compromise product integrity.
2. Regulatory Evolution in India
India’s pharmaceutical regulatory landscape has evolved significantly, particularly with the introduction of modern Good Distribution Practice (GDP) requirements.
Enhanced GMP requirements including storage and monitoring conditions.
Introduced continuous monitoring and stronger documentation requirements.
Increased inspections and compliance verification.
3. International Cold Chain Standards
Export markets require compliance with global regulatory frameworks including WHO TRS 961, US FDA requirements, and EU GDP guidelines.
| Requirement | WHO TRS 961 | US FDA | EU GDP | CDSCO GDP |
|---|---|---|---|---|
| Continuous Monitoring | Required | Required | Required | Required |
| Electronic Records | Recommended | 21 CFR Part 11 | Required | Required |
| Temperature Mapping | Required | Required | Required | Required |
| Deviation Management | Required | Required | Required | Required |
| Transport Monitoring | Required | Required | Required | Emerging |
4. The Path Forward
The convergence of regulatory pressure and export market demands presents both challenges and opportunities for Indian pharmaceutical distributors.
Modern IoT-enabled monitoring systems now provide continuous temperature tracking, automated alerts, and secure electronic records that simplify compliance.
Organizations that adopt these technologies will gain advantages including:
- Reduced product loss from temperature excursions
- Audit-ready regulatory documentation
- Access to premium export markets
- Improved supply chain transparency
For companies committed to quality and growth, technology-enabled cold chain compliance is not merely a regulatory requirement—it is a strategic capability.
References
- CDSCO. Guidelines on Good Distribution Practices for Pharmaceutical Products, 2022.
- WHO. Technical Report Series 961 – Storage and Transport of Temperature Sensitive Pharmaceutical Products.
- WHO Immunization Coverage Report.
- Pharmexcil Export Data.
- US FDA – 21 CFR Part 11.
- EU GDP Guidelines (2013/C 343/01).
Disclaimer: Informational only. Not regulatory advice.
Published: February 2026